Lupin – Recall of quinapril

- On December 21, 2022, the FDA announced a consumer level recall of four lots of Lupin's quinapril tablets due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, above the acceptable daily intake level.
- These recalled lots were distributed March 2021 – September 2022. Lupin discontinued the marketing of quinapril tablets in September 2022.

Product Description	NDC#	Lot# (Expiration Date)
Quinapril 20 mg tablets, 90 count bottle	68180-558-09	G102929 (4/2023)
Quinapril 40 mg tablets, 90 count bottle	68180-554-09	G100533 (12/2022); G100534 (12/2022); G203071 (3/2024)

- Quinapril is indicated for the treatment of hypertension, to lower blood pressure.
- Nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.
- To date, Lupin has not received any reports of adverse events related to this recall.
- Patients who have the recalled quinapril are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.
- Patients who have the recalled quinapril should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled product.
- Wholesalers, distributors and retailers with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Contact Inmar (appointed company for Lupin) at **1-877-538-8445** for more information.